Shares of small-cap penny stock Bluejay Diagnostics, Inc. BJDX are trading higher after the company announced that the FDA has agreed to consider its plan to pursue a De Novo submission for the Symphony IL-6 Test.
Neil Dey, Chief Executive Officer, said “This confirms our belief that the Bluejay Symphony IL-6 Test has the potential to provide an innovative solution to the market. Bluejay continues to advance the Symphony IL-6 Test towards the Company’s anticipated marketing application with the FDA, expected by year-end 2022.”
Bluejay Diagnostics develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States.
Bluejay Diagnostics, Inc. shares were trading about 30% higher at $1.68 per share on Thursday at the time of publication.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
